Beranda0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Tutup sebelumnya
$1,01
Rentang hari
$0,89 - $1,01
Rentang tahun
$0,40 - $1,10
Kapitalisasi pasar
8,55 M HKD
Volume Rata-Rata
9,06 jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
HKG
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (HKD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,30 M | -1,14% |
Biaya operasional | 413,65 jt | 27,86% |
Penghasilan bersih | -75,42 jt | -15.168,63% |
Margin laba bersih | -5,79 | -14.575,00% |
Penghasilan per saham | — | — |
EBITDA | 4,66 jt | -95,31% |
Tarif pajak efektif | -11,85% | — |
Neraca
Total aset
Total liabilitas
| (HKD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 797,84 jt | 41,94% |
Total aset | 11,29 M | 3,66% |
Total liabilitas | 7,63 M | 11,04% |
Total ekuitas | 3,65 M | — |
Saham yang beredar | 9,61 M | — |
Harga terhadap nilai buku | 2,66 | — |
Tingkat pengembalian aset | -0,37% | — |
Tingkat pengembalian modal | -0,41% | — |
Arus Kas
Perubahan kas bersih
| (HKD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -75,42 jt | -15.168,63% |
Kas dari operasi | -3,03 jt | -104,17% |
Kas dari investasi | 9,20 jt | 119,22% |
Kas dari pembiayaan | 103,54 jt | 233,22% |
Perubahan kas bersih | 118,57 jt | 305,99% |
Arus kas bebas | -33,81 jt | -290,23% |
Tentang
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
Didirikan
2000
Situs
Karyawan
1.935
